Humanized, Nonmitogenic OKT3 Antibody, huOKT3 (Ala-Ala): Initial Clinical Experience

By Woodle E.S.   Bluestone J.A.   Zivin R.A.   Jolliffe L.K.   Auger J.   Xu D.   Thistlethwaite J.R.  

Transplantation Proceedings, Vol. 30, Iss. 4, 1998-06 ,pp. : 1369-1370

Elsevier

Access to resources Recommend Favorite

Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo

By Carpenter P.A.   Tso J.Y.   Press O.W.   Yu X.-Z.   Anasetti C.  

Transplantation Proceedings, Vol. 32, Iss. 7, 2000-11 ,pp. : 1545-1546

Elsevier

Access to resources Recommend Favorite

Characterization of anti-Thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA

By Regan J.   Campbell K.   Van Smith L.   Pouletty P.   Schroeder T.J.   Guttman R.D.   Buelow R.  

Transplant Immunology, Vol. 5, Iss. 1, 1997-03 ,pp. : 49-56

Elsevier

Access to resources Recommend Favorite

Use of reduced dose of OKT3 (2.5 mg) after renal transplantation

By Machado P.G.P.   Tedesco H.S.   Silva R.G.   Pacheco-Silva A.   Medina J.O.P.  

Transplantation Proceedings, Vol. 34, Iss. 1, 2002-02 ,pp. : 104-104

Elsevier

Access to resources Recommend Favorite

A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results

By Baldi A.   Malaise J.   Mourad M.   Squifflet J.P.  

Transplantation Proceedings, Vol. 32, Iss. 2, 2000-03 ,pp. : 429-431

Elsevier

Access to resources Recommend Favorite